Irit Ben-Chelouche

Director of Business Development, Harvard Medical School

Displaying: 11 - 20 of 36 Results

Trpa1 conditional knockout mice

The mouse strain 129S-Trpa1tm2Kykw/J was developed by Kelvin Kwan in the laboratory of HHMI Investigator David Corey at Harvard Medical School. Trpa1 conditional knockout animals were generated by flanking the exons that code for the pore domain of…

Investigators

  • Kelvin Y. Kwan
  • David P. Corey

TRPA1 knockout mice developed in the laboratory of Professor David Corey

Homozygous Transient Receptor Potential Cation Channel Subfamily A Member 1 (TRPA1) mutant mice (B6;129P-Trpa1tm1Kykw/J, also known as Trpa1 KO) were developed by HHMI Investigator David Corey at Harvard Medical School. They exhibit abnormal…

Investigators

  • David P. Corey

Targeting fatty acid oxidation for treatment of cancer, including AML, prostate, breast and colon cancers

Several cancers are characterized by slow glycolysis and rely on non-glycolytic pathways such as fatty acid oxidation (FAO) as their main source of energy. While dependency of cancer cells on FAO has been known, the underlying mechanistic…

Investigators

  • Marcia C. Haigis

Intracellular delivery of proteins: Aurin 1.2, an efficient non-endosomal protein delivery platform

To fully realize the therapeutic potential of proteins, exogenous proteins need to access intracellular targets. Since the vast majority of proteins cannot spontaneously cross cell membranes, a range of delivery platforms have been developed. These…

Investigators

  • David R. Liu

Using evolutionary coupling methodology and other unique computational biology tools to advance pharmaceutical development

The prediction of drug effects is a long-standing challenge in the biomedical data community and pharmaceutical industry. As new candidate target genes emerge from successful CRISPR and GWAS screens, assessing ‘anti-targets’ and exploiting…

Investigators

  • Debora Marks

Liquid biopsy-based predictive platform for early cancer detection and drug discovery

Recognition and management of individuals susceptible to disease are critical for patient care. However, identification of these patients is very challenging, especially in oncology. Dr. Peter Park and his group at the Department of Biomedical…

Investigators

  • Peter Park

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes

First in class substrate-selective Insulin Degrading Enzyme (IDE) inhibitors for treating Diabetes. Professor David Liu and a multidisciplinary research team have recently discovered and optimized of a series of small molecules (<550 Da, IC50 = 1…

Investigators

  • David R. Liu
  • Juan Pablo Maianti

Therapeutic strategies for autism spectrum disorder sensory (tactile) hypersensitivity, anxiety and social interaction deficits

This is a novel strategy to treat tactile hypersensitivity, anxiety, and social interaction deficits by targeting the peripheral nervous system without drugging the brain.Autism spectrum disorders (ASDs), including Rett Syndrome, as well as Fragile…

Investigators

  • David Ginty
  • Lauren Orefice

A novel and effective technology for target-based screening

Target-based screening allows for rapid identification of ligands for an increasing number of macromolecular targets and is commonly used in drug discovery.The present invention uses interaction-dependent PCR (IDPCR) to selectively identify…

Investigators

  • David R. Liu
  • Christoph E. Dumelin
  • David J. Gorin
  • Lynn McGregor

Targeting autophagy for the treatment of neurological diseases

Neurodegenerative diseases occur due to the progressive loss of function and death of neurons, often caused by the accumulation of misfolded proteins. Consequently, increasing the degradation of misfolded proteins and preventing cell death could be…

Investigators

  • Junying Yuan

Page 2 of 4